Hussein Sultan, PhD

Hussein Sultan, PhD

Instructor, Pathology & Immunology

Division

  • Immunobiology

Twitter Handle

Research Areas of Interest

  • My utmost motivation lies in enhancing the safety and effectiveness of cancer immunotherapy, with specific emphasis on personalized neoantigen cancer vaccines. 
  • My research focuses on two main areas:
    • Define the intrinsic and extrinsic factors that lead to the induction/development of type 1 regulatory T cells and unravel the mechanisms involved in their suppressive activity. 
    • Develop novel vaccination strategies that promote the induction of effector anti-tumor T cells while avoiding the generation of suppressive T-cell responses that promote tumor progression.

Publications

Sultan H, Takeuchi Y, Ward JP, Sharma N, Liu TT, Sukhov V, Firulyova M, Song Y, Ameh S, Brioschi S, Khantakova D, Arthur CD, White JM, Kohlmiller H, Salazar AM, Burns R, Costa HA, Moynihan KD, Yeung YA, Djuretic I, Schumacher TN, Sheehan KCF, Colonna M, Allison JP, Murphy KM, Artyomov MN, Schreiber RD. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug;632(8023):182-191. doi: 10.1038/s41586-024-07752-y. Epub 2024 Jul 24. PMID: 39048822; PMCID: PMC11291290.
Meng W, Takeuchi Y, Ward JP, Sultan H, Arthur CD, Mardis ER, Artyomov MN, Lichti CF, Schreiber RD. Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry. Cancer Immunol Res. 2024 Aug 1;12(8):988-1006. doi: 10.1158/2326-6066.CIR-23-0900. PMID: 38768391.

Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, Bessette P, Lan RY, Nguyen HC, Mathewson ND, Ni I, Chen W, Lee Y, Liao-Chan S, Chen J, Schumacher TNM, Schreiber RD, Yeung YA, Djuretic IM. IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity. Cancer Discov. 2024 Jul 1;14(7):1206-1225. doi: 10.1158/2159-8290.CD-23-1266. PMID: 38563906; PMCID: PMC11215410.
Sultan H, Salazar AM, Celis E. Poly-ICLC, a multi-functional immune modulator for treating cancer. Semin Immunol. 2020 Jun;49:101414. doi: 10.1016/j.smim.2020.101414. Epub 2020 Oct 1. PMID: 33011064.
Sultan H, Fesenkova VI, Addis D, Fan AE, Kumai T, Wu J, Salazar AM, Celis E. Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunol Immunother. 2017 Feb;66(2):203-213. doi: 10.1007/s00262-016-1834-5. Epub 2016 Apr 6. PMID: 27052572; PMCID: PMC5053837.
Sultan H, Kumai T, Nagato T, Wu J, Salazar AM, Celis E. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunol Immunother. 2019 Mar;68(3):455-466. doi: 10.1007/s00262-018-02294-5. Epub 2019 Jan 2. PMID: 30604041; PMCID: PMC6428613.
Sultan H, Wu J, Fesenkova VI, Fan AE, Addis D, Salazar AM, Celis E. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. J Immunother Cancer. 2020 Sep;8(2):e001224. doi: 10.1136/jitc-2020-001224. PMID: 32958686; PMCID: PMC7507896.
Kumai T, Lee S, Cho HI, Sultan H, Kobayashi H, Harabuchi Y, Celis E. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses. Cancer Immunol Res. 2017 Jan;5(1):72-83. doi: 10.1158/2326-6066.CIR-16-0194. Epub 2016 Dec 9. PMID: 27941004; PMCID: PMC5221568.
Sultan H, Trillo-Tinoco J, Rodriguez P, Celis E. Effective antitumor peptide vaccines can induce severe autoimmune pathology. Oncotarget. 2017 Jul 29;8(41):70317-70331. doi: 10.18632/oncotarget.19688. PMID: 29050282; PMCID: PMC5642557.

Assistant
Jeanne Grigsby
314-747-0561
jmgrigsby@wustl.edu

Lab Phone: 314-362-8746
Office Location: BJC-IH Building, Office Suite C  8417